[1]蔡庆宇,刘海洲.利伐沙班和低分子肝素钙预防中重度脑出血术后下肢深静脉血栓形成的效果比较[J].医学信息,2021,34(08):150-152.[doi:10.3969/j.issn.1006-1959.2021.08.040]
　CAI Qing-yu,LIU Hai-zhou.Comparison of the Effects of Rivaroxaban and Low-molecular-weight Heparin Calcium in Preventing Deep Vein Thrombosis of Lower Extremities After Moderate to Severe Intracerebral Hemorrhage[J].Medical Information,2021,34(08):150-152.[doi:10.3969/j.issn.1006-1959.2021.08.040]
点击复制

利伐沙班和低分子肝素钙预防中重度脑出血术后下肢深静脉血栓形成的效果比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年08期
页码:
150-152
栏目:
药物与临床
出版日期:
2021-04-15

文章信息/Info

Title:
Comparison of the Effects of Rivaroxaban and Low-molecular-weight Heparin Calcium in Preventing Deep Vein Thrombosis of Lower Extremities After Moderate to Severe Intracerebral Hemorrhage
文章编号:
1006-1959（2021）08-0150-03
作者:
蔡庆宇; 刘海洲
（1.佳木斯市中医院内一科，黑龙江 佳木斯 154002； 2.北京中医药大学附属第三医院推拿科，北京 100029）
Author(s):
CAI Qing-yu; LIU Hai-zhou
(1.The First Department of Internal Medicine,Jiamusi Traditional Chinese Medicine Hospital,Jiamusi 154002,Heilongjiang,China; 2.Department of Tuina,the Third Affiliated Hospital of Beijing University of Chinese Medicine,Beijing 100029,China)
关键词:
利伐沙班; 低分子肝素钙; 脑出血; 深静脉血栓
Keywords:
Rivaroxaban; Low molecular weight heparin calcium; Intracerebral hemorrhage; Deep venous thromborsis
分类号:
R743.34；R543.6
DOI:
10.3969/j.issn.1006-1959.2021.08.040
文献标志码:
A
摘要:
目的 比较利伐沙班和低分子肝素钙预防中重度脑出血后下肢深静脉血栓（DVT）形成的有效性及安全性。方法 选择佳木斯市中医院2019年1月~12月收治的中重度ICH术后患者83例，采取随机数字表法分为利伐沙班组（n=42）和低分子肝素钙组（n=41）。利伐沙班组采用利伐沙班治疗，低分子肝素钙组采用低分子肝素钙治疗。比较两组患者DVT发生率、凝血功能指标[血小板计数（PLT）、纤维蛋白原（Fib）、凝血酶原时间（PT）、部分凝血活酶时间（APTT）、D-二聚体（D-D）]、不良反应发生情况。结果 利伐沙班组DVT发生率为4.76%，低分子肝素钙组DVT发生率为7.31%，两组患者DVT发生率比较，差异无统计学意义（P＞0.05）；两组患者PT、APTT均升高，PLT、Fib、D-D均降低，差异有统计学意义（P＜0.05）；利伐沙班组PT、APTT高于低分子肝素钙组，PLT、Fib、D-D低于低分子肝素钙组，差异有统计学意义（P＜0.05）；两组患者均未出现牙龈出血、皮下瘀斑、黑便、血尿、眼底出血、鼻衄、颅内再出血等不良反应。结论 利伐沙班和低分子肝素钙预防中重度ICH术后DVT的有效性和安全性均较好，且利伐沙班改善凝血功能效果更佳。
Abstract:
Objective To compare the effectiveness and safety of rivaroxaban and low-molecular-weight heparin calcium in preventing the formation of deep vein thrombosis (DVT) of the lower extremities after moderate to severe intracerebral hemorrhage.Methods A total of 83 patients with moderate to severe ICH who were admitted to Jiamusi Traditional Chinese Medicine Hospital from January to December 2019 were selected.A random number table was used to divide them into the rivaroxaban group (n=42) and the low-molecular-weight heparin calcium group (n=41).The rivaroxaban group was treated with rivaroxaban, and the low-molecular-weight heparin calcium group was treated with low-molecular-weight heparin calcium.The incidence of DVT and coagulation function indexes [platelet count (PLT), fibrinogen (Fib), prothrombin time (PT), partial thromboplastin time (APTT), and D-dimer (D-D) were compared between the two groups of patients], the occurrence of adverse reactions.Results The incidence of DVT in the rivaroxaban group was 4.76%, and the incidence of DVT in the low molecular weight heparin calcium group was 7.31%. There was no significant difference in the incidence of DVT between the two groups (P>0.05);The PT and APTT of the two groups were all increased, while PLT, Fib, and D-D were all decreased, the difference was statistically significant (P＜0.05);The PT and APTT of the rivaroxaban group were higher than the low-molecular-weight heparin calcium group, and the PLT, Fib, and D-D were lower than the low-molecular-weight heparin calcium group, the difference was statistically significant (P＜0.05);There were no adverse reactions such as gum bleeding, subcutaneous ecchymosis, melena, hematuria, fundus bleeding, epistaxis, intracranial hemorrhage, etc. in both groups.Conclusion Rivaroxaban and low-molecular-weight heparin calcium are effective and safe in preventing moderate to severe ICH postoperative DVT, and rivaroxaban is more effective in improving coagulation function.

参考文献/References:

[1]Veltkamp R,Purrucker J.Management of Spontaneous Intracerebral Hemorrhage[J].Curr Neurol Neurosci Rep,2017,17(10):80. [2]Kim JY,Bae HJ.Spontaneous Intracerebral Hemorrhage:Management[J].J Stroke,2017,19(1):28-39. [3]Mustafa J,Asher I,Sthoeger Z.Upper Extremity Deep Vein Thrombosis:Symptoms,Diagnosis,and Treatment[J].Isr Med Assoc J,2018,20(1):53-57. [4]Comerota AJ,Kearon C,Gu CS,et al.Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis[J].Circulation,2019,139(9):1162-1173. [5]Cheng X,Zhang L,Xie NC,et al.High Plasma Levels of D-Dimer Are Independently Associated with a Heightened Risk of Deep Vein Thrombosis in Patients with Intracerebral Hemorrhage[J].Mol Neurobiol,2016,53(8):5671-5678. [6]郝飒.低分子肝素钙对剖宫产术后产妇凝血功能及下肢深静脉血栓形成的影响[J].内蒙古医学杂志,2020,52(9):1070-1071. [7]秦征东,葛欣.应用低分子肝素钙预防高血压性脑出血术后深静脉血栓形成的疗效和安全性[J].中国医药,2018,13(4):541-544. [8]中华医学会神经病学分会.中国脑出血诊治指南(2014)[J].中华神经科杂志,2015,48(6):435-444. [9]桢妹.彩色多普勒超声在下肢深静脉血栓诊断中的应用价值分析[J].医学理论与实践,2017,30(22):3393-3394. [10]Anand SS,Bosch J,Eikelboom JW,et al.Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease:an international,randomised,double-blind,placebo-controlled trial[J].Lancet,2018,391(10117):219-229. [11]Dangas GD,Tijssen JGP,Wohrle J,et al.A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement[J].N Engl J Med,2020,382(2):120-129. [12]Anand SS,Eikelboom JW,Dyal L,et al.Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial[J].J Am Coll Cardiol,2019,73(25):3271-3280. [13]Zannad F,Anker SD,Byra WM,et al.Rivaroxaban in Patients with Heart Failure,Sinus Rhythm,and Coronary Disease[J].N Engl J Med,2018,379(14):1332-1342. [14]Zhang YM,Jiang X,Sun YS.Effect of rivaroxaban on preventing deep vein thrombosis in aged diabetics with femoral neck fractures after hip replacement[J].Biosci Rep,2017,37(3):BSR20170289.

相似文献/References:

[1]庞永华,陈伟南,许科峰,等.TKA应用氨甲环酸后序贯应用两种新型口服抗凝药预防VTE的疗效对比[J].医学信息,2022,35(09):100.[doi:10.3969/j.issn.1006-1959.2022.09.025]
　PANG Yong-hua,CHEN Wei-nan,XU Ke-feng,et al.Comparison of Efficacy of Sequential Application of Two New Oral Anticoagulants in the Prevention of VTE After Application of Tranexamic Acid in TKA[J].Medical Information,2022,35(08):100.[doi:10.3969/j.issn.1006-1959.2022.09.025]
[2]邹万芹,孙立军.地屈孕酮联合低分子肝素钙治疗先兆流产患者的效果[J].医学信息,2019,32(14):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
　ZOU Wan-qin,SUN Li-jun.Effect of Dydrogesterone Combined with Low Molecular Weight Heparin Calcium in Patients with Threatened Abortion[J].Medical Information,2019,32(08):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
[3]杨利中,冯欢欢,刘 华,等.桃红四物汤联合氨甲环酸对人工股骨头置换术后 隐形失血的影响[J].医学信息,2019,32(17):150.[doi:10.3969/j.issn.1006-1959.2019.17.050]
　YANG Li-zhong,FENG Huan-huan,LIU Hua,et al.Effect of Taohong Siwu Decoction Combined with Tranexamic Acid on Invisible Blood Loss after Artificial Femoral Head Replacement[J].Medical Information,2019,32(08):150.[doi:10.3969/j.issn.1006-1959.2019.17.050]
[4]贾科锋,魏召劝,郭亚堂,等.阿哌沙班与低分子肝素钠在膝关节置换术后抗凝治疗的对比[J].医学信息,2022,35(15):55.[doi:10.3969/j.issn.1006-1959.2022.15.011]
　JIA Ke-feng,WEI Zhao-quan,GUO Ya-tang,et al.Comparison of Anticoagulant Therapy Between Apixaban and Low Molecular Heparin Sodium After Knee Arthroplasty[J].Medical Information,2022,35(08):55.[doi:10.3969/j.issn.1006-1959.2022.15.011]
[5]张丽娜,张胜英.低分子肝素钙预防高危产妇剖宫产术后下肢静脉血栓的临床观察[J].医学信息,2019,32(21):95.[doi:10.3969/j.issn.1006-1959.2019.21.029]
　ZHANG Li-na,ZHANG Sheng-ying.Clinical Observation of Low Molecular Weight Heparin Calcium in Prevention of Lower Extremity Venous Thrombosis after High-Risk Maternal Cesarean Section[J].Medical Information,2019,32(08):95.[doi:10.3969/j.issn.1006-1959.2019.21.029]

更新日期/Last Update: 1900-01-01